- Home
- VANI vs IMAB Comparison
VANI vs IMAB Comparison
Compare VANI & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VANI
- IMAB
- Stock Information
- Founded
- VANI 1998
- IMAB 2014
- Country
- VANI United States
- IMAB United States
- Employees
- VANI N/A
- IMAB N/A
- Industry
- VANI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- VANI Health Care
- IMAB Health Care
- Exchange
- VANI Nasdaq
- IMAB Nasdaq
- Market Cap
- VANI 68.1M
- IMAB 73.9M
- IPO Year
- VANI 2014
- IMAB 2020
- Fundamental
- Price
- VANI $1.26
- IMAB $1.31
- Analyst Decision
- VANI Strong Buy
- IMAB Strong Buy
- Analyst Count
- VANI 1
- IMAB 2
- Target Price
- VANI $4.00
- IMAB $5.50
- AVG Volume (30 Days)
- VANI 66.4K
- IMAB 238.6K
- Earning Date
- VANI 05-13-2025
- IMAB 05-15-2025
- Dividend Yield
- VANI N/A
- IMAB N/A
- EPS Growth
- VANI N/A
- IMAB N/A
- EPS
- VANI N/A
- IMAB N/A
- Revenue
- VANI N/A
- IMAB N/A
- Revenue This Year
- VANI N/A
- IMAB N/A
- Revenue Next Year
- VANI N/A
- IMAB N/A
- P/E Ratio
- VANI N/A
- IMAB N/A
- Revenue Growth
- VANI N/A
- IMAB N/A
- 52 Week Low
- VANI $0.91
- IMAB $0.60
- 52 Week High
- VANI $2.09
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- VANI 77.37
- IMAB 76.59
- Support Level
- VANI $1.13
- IMAB $0.90
- Resistance Level
- VANI $1.16
- IMAB $1.47
- Average True Range (ATR)
- VANI 0.05
- IMAB 0.10
- MACD
- VANI 0.02
- IMAB 0.04
- Stochastic Oscillator
- VANI 92.86
- IMAB 74.07
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).